Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment
Crossref DOI link: https://doi.org/10.1007/s00125-016-4017-1
Published Online: 2016-06-15
Published Print: 2016-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fioretto, Paola
Stefansson, Bergur V.
Johnsson, Eva
Cain, Valerie A.
Sjöström, C. David
Funding for this research was provided by:
AstraZeneca
License valid from 2016-06-15